Protherics WKN883107 ab Januar werden BSE-Tests in ganz Europa Pflicht!! - 500 Beiträge pro Seite

[Krau]

so billig sehen wir diese Aktie nicht mehr!
absolut unentdeckt!

Products marketed - niche markets

BSE Diagnostic Test

Protherics` licensee, Enfer Scientific has developed a robust, high
throughput assay validated in studies by the Department of Agriculture
veterinary research laboratory. The test has generated modest revenues.

More recently, EC interest in BSE diagnosis, arising from increasing
evidence of BSE infection in several European countries, led to the
evaluation of a four potential BSE tests, including the Enfer test, by the
European Commission. The results showed that the Enfer test was 100%
accurate and was the fastest assay system available. Click here for futher
details in our press release. The Commission`s published report on the test
evaluations can be downloaded from this link.

mfg Krau

[sorcer]

hallo krau
danke für die info kannst du mir die webside der firma
nennen um den gesamten bericht lesen zu können?
danke und gruß

[Krau]

www.protherics.com

bis jetzt noch kaum Umsätze, aber ich denke,
dass wird sich ändern!!

mfg Krau

[Krau]

Hier der gesamte Artikel!!
und schaut euch mal die Umsätze in London an!!

5 July 1999

European Commission Evaluates BSE Tests

Proteus/Enfer Test Shows "Remarkable Effectiveness and … 100% Success Rate"

Proteus International plc has noted the recent announcement from the European Commission concerning its evaluation of tests for BSE. The report concluded:

"Three rapid post-mortem BSE tests have shown remarkable effectiveness and achieved a 100% success rate in distinguishing animals clinically affected with BSE from
healthy animals."

The most rapid test, taking just four hours to complete compared with up to 24 hours for the others, was developed by Enfer Scientific, licensee of Proteus’ BSE antibody
technology. Speed in testing is seen as an important advantage when monitoring beef carcasses for BSE prior to release into the human food chain.

The BSE test evaluation programme was managed by the EC Directorate General for Consumer Policy and Consumer Health Protection who issued an open worldwide
call to participate in a comparative Community evaluation programme. Ten tests were submitted, four of which were finally selected by a group of independent scientists
for inclusion in a comprehensive validation study. In the study, each participating laboratory was asked to assay 1400 coded post-mortem samples taken from BSE
affected or BSE free beef carcasses. On the basis of this study, the Enfer test has now been declared as the fastest, specific test for BSE in the world.

The Enfer testing system, which is commercially available, is a post-mortem test using ELISA technology allowing the detection of the disease-specific prion protein
PrPsc in central nervous tissue. This system uses novel technology that allows rapid testing (less than 4 hours) of animal carcasses for PrPsc. It is a complete integrated
robust test system capable of processing approximately 1000 samples per day, per system, with results available before carcasses are released to enter the human food
chain. The system is 100% accurate as this independent validation concludes.

The testing system has been developed specifically to allow the beef producer to elevate the status of beef. Consumer Commissioner Emma Bonino has stated that the
test is "very promising for our fight against BSE and could have a role in enhancing consumer safety, in particular by improving surveillance."

Commenting on the EC announcement, David Gration, Chairman of Proteus said:

"This is a major achievement by Enfer and should be taken seriously by all parties involved in protecting the consumer and promoting trade in beef products across
Europe and beyond."

David Gration, Chairman

Proteus International plc
Tel: [phone]
Tim Anderson / Lisa Baderoon

Buchanan Communications
Tel: [phone]

mfg Krau

[Krau]

Hier noch was allgemeines zu Protherics

Protherics PLC was formed in September 1999 from the merger of
Proteus International plc and Therapeutic Antibodies Inc.
Complementary product portfolios and management teams created a
foundation for a strong and focused business. Protherics PLC has two
products under regulatory review with the US Food and Drug
Administration, a further four products in clinical trials and three
products in early stage development.

The company has research and development laboratories in
Macclesfield in the UK, GMP compliant manufacturing facilities in
Wales and Australia, and clinical development and regulatory affairs
facilities in Macclesfield and Nashville, Tennessee, USA.

"We believe that through state of the art technology
we can improve the management of human disease."

To achieve this mission we recognise that our first goal is to build a
self-sustaining, financially viable, biopharmaceutical business. Our
strategy is to use revenues from our niche products, now entering
the market, to support our ongoing research and development
programs addressing much larger markets with unmet medical
needs.


Protherics` Products

Protherics` products are based upon three advanced and proprietary
technology platforms; passive antibody therapies, active
immunotherapeutics, and rational computer aided molecular design.
See the "Technology" pages for more information.

mfg Krau

[Krau]

hier noch etwas zur Unternehmensstrategie!!

Protherics PLC was formed in September 1999 from the merger of
Proteus International plc and Therapeutic Antibodies Inc.
Complementary product portfolios and management teams created a
foundation for a strong and focused business. Protherics PLC has two
products under regulatory review with the US Food and Drug
Administration, a further four products in clinical trials and three
products in early stage development.

The company has research and development laboratories in
Macclesfield in the UK, GMP compliant manufacturing facilities in
Wales and Australia, and clinical development and regulatory affairs
facilities in Macclesfield and Nashville, Tennessee, USA.

"We believe that through state of the art technology
we can improve the management of human disease."

To achieve this mission we recognise that our first goal is to build a
self-sustaining, financially viable, biopharmaceutical business. Our
strategy is to use revenues from our niche products, now entering
the market, to support our ongoing research and development
programs addressing much larger markets with unmet medical
needs.


Protherics` Products

Protherics` products are based upon three advanced and proprietary
technology platforms; passive antibody therapies, active
immunotherapeutics, and rational computer aided molecular design.
See the "Technology" pages for more information.

mfg Krau